Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer

Oncology Reports

Volumn 33, Issue 1, 2015, Pages 49-57

  Shan, Yan Shen ^a   Hsu, Hui Ping ^a   Lai, Ming Derg ^b   Yen, Meng Chi ^b,c   Luo, Yi Pey ^d   Chen, Yi Ling ^d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Argininosuccinate synthetase; Gastric cancer; Recurrence free survival

Indexed keywords

ARGININOSUCCINATE SYNTHASE; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOPLASM; ENZYME ACTIVITY; EPITHELIUM; FEMALE; GENE EXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; PERINEURAL INVASION; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECURRENCE FREE SURVIVAL; STOMACH ADENOCARCINOMA; STOMACH CANCER; TUMOR VOLUME; UNIVERSITY HOSPITAL; WESTERN BLOTTING; ADENOCARCINOMA; AGED; DISEASE FREE SURVIVAL; ENZYMOLOGY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; STOMACH TUMOR;

ADENOCARCINOMA; AGED; ARGININOSUCCINATE SYNTHASE; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84916242533     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3556     Document Type: Article

References (37)

1. Alberts SR, Cervantes A and van de Velde CJ: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14 (Suppl 2): ii31-ii36, 2003.
2. Roder DM: The epidemiology of gastric cancer. Gastric Cancer 5 (Suppl 1): 5-11, 2002.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
4. Yoo CH, Noh SH, Shin DW, Choi SH and Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg 87: 236-242, 2000.
5. Sakamoto Y, Ohyama S, Yamamoto J, et al: Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery 133: 507-511, 2003.
6. Kroemer G and Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482, 2008.
7. Pinheiro JPV and Boos J: The best way to use asparaginase in childhood acute lymphatic leukaemia-still to be defined? Br J Haematol 125: 117-127, 2004.
8. Morris SM Jr: Enzymes of arginine metabolism. J Nutr 134: 2743S-2747S; discussion 2765S-2767S, 2004.
9. Freytag SO, Beaudet AL, Bock HG and O'Brien WE: Molecular structure of the human argininosuccinate synthetase gene: occurrence of alternative mRNA splicing. Mol Cell Biol 4: 1978-1984, 1984.
10. Ensor CM, Holtsberg FW, Bomalaski JS and Clark MA: Pegylated arginine deiminase (ADI-SS PEG 20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62: 5443-5450, 2002.
11. Feun LG, Marini A, Walker G, et al: Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 106: 1481-1485, 2012.
12. Bowles TL, Kim R, Galante J, et al: Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 123: 1950-1955, 2008.
13. Delage B, Fennell DA, Nicholson L, et al: Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126: 2762-2772, 2010.
14. Wu MS, Lin YS, Chang YT, Shun CT, Lin MT and Lin JT: Gene expression profiling of gastric cancer by microarray combined with laser capture microdissection. World J Gastroenterol 11: 7405-7412, 2005.
15. Szlosarek PW, Grimshaw MJ, Wilbanks GD, et al: Aberrant regulation of argininosuccinate synthetase by TNF-alpha in human epithelial ovarian cancer. Int J Cancer 121: 6-11, 2007.
16. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol 17: 1471-1474, 2010.
17. Remmele W and Schicketanz KH: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 189: 862-866, 1993.
18. Shan YS, Fang JH, Lai MD, et al: Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules. Mol Carcinog 50: 739-750, 2011.
19. Rhodes DR, Yu J, Shanker K, et al: ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6, 2004.
20. Aguirre-Gamboa R, Gomez-Rueda H, Martinez-Ledesma E, et al: SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. Plos One 8: e74250, 2013.
21. Cho JY, Lim JY, Cheong JH, et al: Gene expression signaturebased prognostic risk score in gastric cancer. Clin Cancer Res 17: 1850-1857, 2011.
22. D'Errico M, de Rinaldis E, Blasi MF, et al: Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer 45: 461-469, 2009.
23. Förster S, Gretschel S, Jons T, Yashiro M and Kemmner W: THBS4, a novel stromal molecule of diffuse-type gastric adenocarcinomas, identified by transcriptome-wide expression profiling. Mod Pathol 24: 1390-1403, 2011.
24. Wang J, Yang YH, Wang AQ, et al: Immunohistochemical detection of the Raf kinase inhibitor protein in nonneoplastic gastric tissue and gastric cancer tissue. Med Oncol 27: 219-223, 2010.
25. Deng NT, Goh LK, Wang HN, et al: A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61: 673-684, 2012.
26. Chen X, Leung SY, Yuen ST, et al: Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 14: 3208-3215, 2003.
27. Ooi CH, Ivanova T, Wu J, et al: Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet 5: e1000676, 2009.
28. Kobayashi E, Masuda M, Nakayama R, et al: Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma. Mol Cancer Ther 9: 535-544, 2010.
29. Orditura M, Galizia G, Sforza V, et al: Treatment of gastric cancer. World J Gastroenterol 20: 1635-1649, 2014.
30. Huang JQ, Sridhar S, Chen Y and Hunt RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114: 1169-1179, 1998.
31. Cao MD, George TJ, Prima V, Nelson D and Svetlov S: Argininosuccinate synthase as a novel biomarker for inflammatory conditions. Biomarkers 18: 242-249, 2013.
32. Conteduca V, Sansonno D, Lauletta G, Russi S, Ingravallo G and Dammacco F: H. pylori infection and gastric cancer: State of the art (Review). Int J Oncol 42: 5-18, 2013.
33. Bornschein J, Kandulski A, Selgrad M and Malfertheiner P: From gastric inflammation to gastric cancer. Dig Dis 28: 609-614, 2010.
34. Gonzalez GG and Byus CV: Effect of dietary arginine restriction upon ornithine and polyamine metabolism during two-stage epidermal carcinogenesis in the mouse. Cancer Res 51: 2932-2939, 1991.
35. Feun L, You M, Wu CJ, et al: Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 14: 1049-1057, 2008.
36. Izzo F, Marra P, Beneduce G, et al: Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies. J Clin Oncol 22: 1815-1822, 2004.
37. Ascierto PA, Scala S, Castello G, et al: Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23: 7660-7668, 2005.